Skip to main content
. Author manuscript; available in PMC: 2017 Oct 15.
Published in final edited form as: J Neuroimmunol. 2016 Sep 3;299:70–78. doi: 10.1016/j.jneuroim.2016.09.002

Table 1.

Properties of anti-ELAVL-positive patients1

Patient Paraneoplastic
Disease		 Gender Age at
diagnosis		 Smoking
History		 Tumor and
stage		 Age
deceased		 Survival
(months)		 Initial response to
treatment
1 PEM/SN F 72 Unknown SCLC, LD 72 0 No treatment
2 PEM/SN F 66 50 pack-years n/a; no SCLC or other tumor 76 n/a n/a
3 PEM/SN F 43 Unknown Primary unclear, ED 45 21 Complete response
4 LEMS M 76 75 pack-years SCLC, LD 84 99 Complete response
5 none F 65 Unknown SCLC, 66 10 Complete response
6 none M 74 Unknown SCLC, LD 74 0 No response
7 none F 55 Previous smoker SCLC, LD 56 8 No response
1

Patients 1-3 were diagnosed with PEM/SN, which is typically associated with anti-ELAVL antibodies; patient 2 showed no detectable tumor in 11–year follow up despite suspected SCLC; patient 3 showed neuroendocrine brain metastasis but no primary tumor at the time -origin of metastasis was unclear since she had a history of ovarian carcinoma and pulmonary metastasis; patient 4 showed anti-ELAVL4 antibodies but exhibited LEMS, which is associated with antibodies against voltage-gated calcium channels; patients 5-7 showed no paraneoplastic autoimmune neurological disease. LD: limited disease, ED: extensive disease.